Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a combination treatment of acalabrutunib when given
together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) to evaluate if it will be
able to improve durable responses and cure some patients.